Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Recruiting · NCT05756569 · Registry updated 2026-07-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, bladder adenocarcinoma, bladder squamous cell carcinoma, bladder urachal adenocarcinoma, malignant renal pelvis neoplasm, neoplasm, ureter cancer, ureteral disorder, urethra cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 2 | 2026-07-29 | NCT05756569 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Astellas Pharma Inc | 43 |
| Emory University | 393 |
| Merck Sharp & Dohme LLC | 650 |
| National Cancer Institute (NCI) | 3015 |
| Seagen Inc. | 31 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory Saint Joseph's Hospital | Atlanta | United States | 175 |
| Emory University Hospital Midtown | Atlanta | United States | 246 |
| Emory University Hospital/Winship Cancer Institute | Atlanta | United States | 299 |
| Grady Health System | Atlanta | United States | 89 |